Regeneron Pharmaceuticals, Inc.
REGN8-K,event date Oct 30, 2026,filed Oct 30, 2026,Original on SEC.gov (opens in a new tab)
5 of 5 risk excerpts located in the filing text
Coverage details
This summary passed the automatic coverage checks when it was generated.
Coverage does not verify every claim. Check the cited sources and the original filing.
The Print
Regeneron reported Q3 2026 total revenues of $5.1B (+36% YoY) and GAAP diluted EPS of $18.45 (+35%), with non-GAAP diluted EPS of $20.07 (+70%).
Total revenues increased 36% to $5.1B from $3.8B. Management attributes the Sanofi collaboration revenue increase to a higher share of profits from antibody commercialization ($2.575B versus $1.456B) driven by higher profits primarily associated with increased Dupixent sales, and to the Sanofi Development Balance being fully repaid as of the end of Q2 2026, which meant it no longer reduced Sanofi collaboration revenue beginning in Q3 2026. GAAP R&D rose 22% to $1.8B, which management attributes to advancement of the clinical pipeline and increased manufacturing activity. GAAP other income (expense), net decreased to $235.9M from $736.5M, primarily due to lower net gains on marketable and other securities.
- Total revenues rose 36% to $5.1B, with collaboration revenue of $3.0B (+52.4%) and net product sales of $1.8B (+13.7%).
- GAAP net income increased 33% to $1.9B; non-GAAP net income increased 67% to $2.2B.
- Sanofi collaboration revenue rose 68% to $2.7B, which management attributes to a higher share of antibody commercialization profits and the full repayment of the Sanofi Development Balance at the end of Q2 2026.
- Dupixent global net sales recorded by Sanofi increased 35% to $6.5B; EYLEA HD U.S. net sales rose 62% to $699M while EYLEA U.S. net sales fell 41% to $400M.
Results That Matter
- Total revenues
- Current period
- $5.1B
- Prior period
- $3.8B
- Change
- +36.3%
Revenue growth was accompanied by a 52.4% increase in collaboration revenue to $3,000.5M and a 13.7% increase in net product sales to $1,805.3M. - Net product sales
- Current period
- $1.8B
- Prior period
- $1.6B
- Change
- +13.7%
EYLEA HD U.S. net product sales increased 62% to $699M on higher sales volumes driven by increased demand, partly offset by a lower net selling price; EYLEA U.S. net product sales decreased 41% to $400M on lower sales volumes as a result of continued competitive pressures and the continued transition of patients to EYLEA HD. - Collaboration revenue
- Current period
- $3.0B
- Prior period
- $2.0B
- Change
- +52.4%
Sanofi collaboration revenue rose 68% to $2,724.0M; Bayer collaboration revenue fell 23% to $266.8M. - Income from operations
- Current period
- $2.0B
- Prior period
- $1.0B
- Change
- +99.5%
Operating income nearly doubled as revenue growth outpaced a 12.5% increase in total operating expenses to $3,067.6M. - Net income
- Current period
- $1.9B
- Prior period
- $1.5B
- Change
- +33.5%
Net income grew more slowly than operating income because other income (expense), net fell to $235.9M from $736.5M, primarily due to lower net gains on marketable and other securities. - Net income per share - diluted (GAAP)
- Current period
- $18.45
- Prior period
- $13.62
- Change
- unavailable
Diluted EPS grew faster than net income as weighted average diluted shares fell to 105.6M from 107.2M. - Non-GAAP net income per share - diluted
- Current period
- $20.07
- Prior period
- $11.83
- Change
- unavailable
Non-GAAP net income rose 67% to $2,150.0M; the prior-year period included a $44.5M income tax charge related to enactment of the OBBBA. - GAAP effective tax rate
- Current period
- 14.7%
- Prior period
- 17.2%
- Change
- −2.5 ppts
The GAAP ETR for the third quarter of 2025 was negatively impacted by the enactment of the "One Big Beautiful Bill Act" or "OBBBA," including a $45 million charge related to the re-measurement of the Company's U.S. net deferred tax assets.
| Metric | Current Period | Prior Period | Change | Investor Takeaway |
|---|---|---|---|---|
| $5.1B | $3.8B | +36.3% | Revenue growth was accompanied by a 52.4% increase in collaboration revenue to $3,000.5M and a 13.7% increase in net product sales to $1,805.3M. | |
| $1.8B | $1.6B | +13.7% | EYLEA HD U.S. net product sales increased 62% to $699M on higher sales volumes driven by increased demand, partly offset by a lower net selling price; EYLEA U.S. net product sales decreased 41% to $400M on lower sales volumes as a result of continued competitive pressures and the continued transition of patients to EYLEA HD. | |
| $3.0B | $2.0B | +52.4% | Sanofi collaboration revenue rose 68% to $2,724.0M; Bayer collaboration revenue fell 23% to $266.8M. | |
| $2.0B | $1.0B | +99.5% | Operating income nearly doubled as revenue growth outpaced a 12.5% increase in total operating expenses to $3,067.6M. | |
| $1.9B | $1.5B | +33.5% | Net income grew more slowly than operating income because other income (expense), net fell to $235.9M from $736.5M, primarily due to lower net gains on marketable and other securities. | |
| $18.45 | $13.62 | unavailable | Diluted EPS grew faster than net income as weighted average diluted shares fell to 105.6M from 107.2M. | |
| $20.07 | $11.83 | unavailable | Non-GAAP net income rose 67% to $2,150.0M; the prior-year period included a $44.5M income tax charge related to enactment of the OBBBA. | |
| 14.7% | 17.2% | −2.5 ppts | The GAAP ETR for the third quarter of 2025 was negatively impacted by the enactment of the "One Big Beautiful Bill Act" or "OBBBA," including a $45 million charge related to the re-measurement of the Company's U.S. net deferred tax assets. |
Earnings Quality & Cash Conversion
GAAP net income of $1,948.7M includes other income (expense), net of $235.9M, which includes net gains on marketable and other securities of $60.3M (versus $577.7M in Q3 2025). Non-GAAP net income of $2,150.0M is the company-defined measure excluding stock-based compensation, intangible asset amortization, litigation settlements, gains on marketable and other securities, and related tax effects. The nine-month period includes $161.3M of temporary manufacturing interruption-related costs within GAAP COGS and $14.8M within GAAP COCM, both excluded from non-GAAP.
Red flag
Red flag
Value Drivers & Capital Allocation
“During the nine months ended September 30, 2026, the Company repurchased $2.3 billion of its common stock. As of September 30, 2026, $2.2 billion remained available for share repurchases under the Company's share repurchase programs.”
Filing statement
“In October 2026, the Company declared a cash dividend of $0.94 per share on the Company's common stock and Class A stock, payable on December 3, 2026 to shareholders of record as of November 20, 2026.”
Filing statement
“In October 2026, the Company and Sanofi amended their antibody collaboration, adding multiple next-generation, long-acting Regeneron-invented antibodies to the alliance. Under the terms of the agreement, the Company received an up-front payment of $1.0 billion, and is entitled to receive up to an additional $7.0 billion in the aggregate upon the achievement of certain development, regulatory, and sales-based milestones.”
Filing statement
Forward Signals
Full-year 2026 guidance updated: GAAP R&D raised to $6.600–$6.735B (from $6.500–$6.635B); non-GAAP R&D raised to $6.050–$6.150B; GAAP SG&A lowered to $2.730–$2.860B; non-GAAP SG&A lowered to $2.400–$2.500B; GAAP gross margin on net product sales raised to approximately 80% (from 78%–79%); non-GAAP gross margin raised to approximately 86%; GAAP and non-GAAP COCM unchanged at $985M–$1.035B and $970M–$1.020B; capital expenditures raised to $1.050–$1.100B; GAAP ETR approximately 14% and non-GAAP ETR approximately 15%. Guidance does not assume completion of any business development transactions not completed as of the date of the press release.
Known trends
- The Sanofi Development Balance was fully repaid as of the end of the second quarter of 2026 and no longer reduced Sanofi collaboration revenue beginning in the third quarter of 2026.
- EYLEA U.S. net product sales decreased primarily due to lower sales volumes as a result of continued competitive pressures and the continued transition of patients to EYLEA HD.
- The Company expects an FDA decision for cemdisiran in generalized myasthenia gravis next month and plans to initiate a Phase 3 study in MASH/MASLD in the fourth quarter of 2026.
Subsequent events
- In October 2026, the Company and Sanofi amended their antibody collaboration, adding multiple next-generation, long-acting Regeneron-invented antibodies; the Company received a $1.0 billion up-front payment with potential for up to an additional $7.0 billion in milestones.
- In October 2026, the Company announced an agreement with BARDA to provide additional supply of Inmazeb for U.S. preparedness against Ebola disease, with deliveries expected beginning in 2027 through 2031.
- In October 2026, the Company declared a cash dividend of $0.94 per share payable December 3, 2026.
“This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales”
Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer
“Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever.”
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer
Risks
Excerpts are the filing’s own words; each heading is the start of its excerpt. Selected excerpts are not a complete risk inventory.
EYLEA U.S. net product sales decreased in the third quarter of 2026, compared to the third quarter…
EYLEA U.S. net product sales decreased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to lower sales volumes as a result of continued competitive pressures and the continued transition of patients to EYLEA HD.
risks associated with litigation and other proceedings and government investigations relating…
risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts)
the potential for any license or collaboration agreement, including Regeneron's agreements…
the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated
changes to drug pricing regulations and requirements and Regeneron's drug pricing strategy…
changes to drug pricing regulations and requirements and Regeneron's drug pricing strategy, including in connection with Regeneron's April 2026 agreements with the U.S. government
the ability of Regeneron to manufacture and manage supply chains for multiple products and product…
the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions
5 of 5 excerpts located in the filing text
Balance Sheet & Liquidity
Leverage: This filing's standardized financial data reports no debt balance under a concept whose scope can be verified. That is an unestablished scope, not zero debt and not a net cash position; no total debt, net debt or debt-to-equity figure is stated.
Liquidity: Cash and marketable securities totaled $18,858.5M at September 30, 2026, versus $18,865.8M at December 31, 2025.
Working capital: The balance sheet is unclassified; total assets rose to $44,405.2M from $40,558.7M, with accounts receivable up to $7,578.6M from $5,741.1M and inventories down to $2,894.6M from $3,200.8M.
Maturities & covenants
- Not disclosed—the press release balance sheet presents long-term debt of $1,987.0M and finance lease liabilities of $720.0M without maturity schedules or covenant terms.
Notable Footnotes
| Item | Impact |
|---|---|
| Non-GAAP measures | Non-GAAP net income of $2,150.0M and non-GAAP diluted EPS of $20.07 exclude stock-based compensation, intangible asset amortization, litigation settlements, gains on marketable and other securities, and related tax effects; the company notes these measures have limitations as they exclude certain recurring expenses. |
| Free cash flow | Nine-month net cash provided by operating activities was $3,675.3M and capital expenditures were $771.0M, yielding free cash flow of $2,904.3M versus $3,158.5M in the prior-year period. |
| Dupixent and Kevzara sales recording | Sanofi records global net product sales of Dupixent and Kevzara, and the Company records its share of profits within Collaboration revenue; Dupixent global net sales were $6,540.5M in Q3 2026. |
| Temporary manufacturing interruption-related costs | Nine-month GAAP COGS included $161.3M and GAAP COCM included $14.8M of temporary manufacturing interruption-related costs, both excluded from non-GAAP measures. |
Ask REGN’s 8-K anything
Answers come from this filing, with cited passages you can check. Try one:
AI-generated. Informational only, not investment advice. May be incomplete or contain errors. The authoritative source is always the original SEC filing.